Immunotherapy is now established as a powerful way to treat cancer and still holds further promise and opportunities that are yet to be fully explored. Immune cells play a key role in selective recognition and effective eradication of cancer cells. Adoptive cell therapy, with either allogeneic or autologous immune cells, has shown unequivocal therapeutic benefits in a substantial fraction of cancer patients. The emerging strategies have been developed to alter antigen specificity of T-cells with different genetic modifications, including introduction of additional chimeric antigen receptor (CAR), as well as the use of specific molecules that crosslink target and effector cells. Although CAR-T cell therapy has been approved for treatment of certain hematological malignancies, solid cancers are often less susceptible to CAR-T cell therapy mostly due to the immunosuppressive nature of the tumor microenvironment, and the lack of optimal targets on the tumor surface. Solid cancers present some formidable barriers to adoptive cell transfer, including suppression of T-cell function and inhibition of T-cell localization. As the field rapidly evolves, a better understanding of how CAR-T cell therapy works in solid cancers is needed for translating that knowledge into improvements in how they are effectively developed and tested, while decreasing toxicity in clinical practice.
We welcome Original Research and Review articles related to cancer immunology and immunotherapy. We are particularly interested in articles describing CAR-T cell therapy against solid cancers. Both laboratory and clinical studies are welcome. Potential topics include, but are not limited to:
- Recent achievements in CAR-T cell therapy for solid cancers, including the current state of CAR T-cell therapy in solid cancers, the concepts being investigated to overcome the barriers as well as approaches aimed at increasing the specificity and safety of CAR-T cell transfer, etc.
- Basic studies of CAR-T cell-based anti-tumor therapy for solid cancers
- Clinical studies with relevance to CAR-T cell therapy for solid cancers
Immunotherapy is now established as a powerful way to treat cancer and still holds further promise and opportunities that are yet to be fully explored. Immune cells play a key role in selective recognition and effective eradication of cancer cells. Adoptive cell therapy, with either allogeneic or autologous immune cells, has shown unequivocal therapeutic benefits in a substantial fraction of cancer patients. The emerging strategies have been developed to alter antigen specificity of T-cells with different genetic modifications, including introduction of additional chimeric antigen receptor (CAR), as well as the use of specific molecules that crosslink target and effector cells. Although CAR-T cell therapy has been approved for treatment of certain hematological malignancies, solid cancers are often less susceptible to CAR-T cell therapy mostly due to the immunosuppressive nature of the tumor microenvironment, and the lack of optimal targets on the tumor surface. Solid cancers present some formidable barriers to adoptive cell transfer, including suppression of T-cell function and inhibition of T-cell localization. As the field rapidly evolves, a better understanding of how CAR-T cell therapy works in solid cancers is needed for translating that knowledge into improvements in how they are effectively developed and tested, while decreasing toxicity in clinical practice.
We welcome Original Research and Review articles related to cancer immunology and immunotherapy. We are particularly interested in articles describing CAR-T cell therapy against solid cancers. Both laboratory and clinical studies are welcome. Potential topics include, but are not limited to:
- Recent achievements in CAR-T cell therapy for solid cancers, including the current state of CAR T-cell therapy in solid cancers, the concepts being investigated to overcome the barriers as well as approaches aimed at increasing the specificity and safety of CAR-T cell transfer, etc.
- Basic studies of CAR-T cell-based anti-tumor therapy for solid cancers
- Clinical studies with relevance to CAR-T cell therapy for solid cancers